迪哲医药: 迪哲医药：2024年年度股东大会会议资料

Core Viewpoint - The company, Dize Pharmaceutical, is preparing for its 2024 Annual General Meeting (AGM) and has outlined various proposals, including changes to its registered capital, amendments to the company’s articles of association, and the election of new independent directors. The company reported significant growth in sales and ongoing advancements in its drug development pipeline, while also addressing its financial performance and governance structure. Group 1: AGM Preparation and Governance - The company has established guidelines for the 2024 AGM to ensure the orderly conduct of the meeting and the protection of shareholder rights [2][3] - Shareholders and their representatives are entitled to speak, inquire, and vote during the AGM, with specific procedures for raising questions and making statements [3][4] - The AGM will utilize both on-site and online voting methods, with detailed instructions provided for participation [6][8] Group 2: Financial Performance - In 2024, the company achieved a sales revenue of 360 million yuan, representing a year-on-year increase of 294.24% [11][31] - The company reported a net loss of approximately 846 million yuan for the year, leading to a proposal not to distribute dividends or issue new shares [34] - Research and development expenses for 2024 were approximately 724 million yuan, a decrease of 10.17% compared to the previous year [31][32] Group 3: Drug Development and Market Position - The company’s core products, including Shuwozhe® and Gaoruizhe®, received regulatory approvals and are expected to drive future sales growth [11][31] - Significant progress has been made in the development of new drugs, with several candidates receiving breakthrough designations from regulatory authorities [12][13] - The company is actively expanding its market sales system and has established a robust supply chain to enhance operational efficiency [15][17] Group 4: Corporate Governance and Board Structure - The company has undergone changes in its board of directors, including the appointment of a new independent director to ensure compliance with governance standards [16] - The board has held multiple meetings to review and approve key decisions, ensuring adherence to legal and regulatory requirements [18][20] - The company emphasizes the importance of independent directors in safeguarding the interests of minority shareholders [20][27]